News & Videos - ONCOPEPTIDES AB [CBOE]

Oncopeptides Chief Financial Officer Holger Lembrer takes office today PR Newswire STOCKHOLM, Jan. 18, 2023 STOCKHOLM , Jan. 18, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (NASDAQ Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases, today announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18 . "I am very pleased that Holger Lembrer...

Oncopeptides appoints Holger Lembrer as Chief Financial Officer PR Newswire STOCKHOLM, Jan. 11, 2023 STOCKHOLM , Jan. 11, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that...

Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer PR Newswire STOCKHOLM, Jan. 4, 2023 STOCKHOLM , Jan. 4, 2023 /PRNewswire/ -- Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides. She replaces Jakob Lindberg ,...

Oncopeptides has announced the Nomination Committee PR Newswire STOCKHOLM, Dec. 22, 2022 STOCKHOLM , Dec. 22, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the...

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH PR Newswire STOCKHOLM, Dec. 12, 2022 STOCKHOLM , Dec. 12, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American...

Oncopeptides provides update on Pepaxto US marketing authorization PR Newswire STOCKHOLM, Dec. 7, 2022 STOCKHOLM , Dec. 7, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto ® (melphalan flufenamide, also called melflufen). The...

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank PR Newswire STOCKHOLM, Nov. 25, 2022 STOCKHOLM , Nov. 25, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered into a renewed unsecured loan facility agreement with the European Investment Bank (EIB),...

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank PR Newswire STOCKHOLM, Nov. 25, 2022 STOCKHOLM , Nov. 25, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered into a renewed unsecured loan facility agreement with the European Investment Bank (EIB),...

Oncopeptides' Pepaxti has been granted marketing authorization in the UK PR Newswire STOCKHOLM, Nov. 11, 2022 STOCKHOLM , Nov. 11, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti ® (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare...

Oncopeptides publishes Q3 report 2022 PR Newswire STOCKHOLM, Nov. 9, 2022 STOCKHOLM , Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022. "The successful directed share issue in July and the approval of Pepaxti ® in EU and EEA-countries in August, set the stage for a new and exciting phase for...

Oncopeptides publishes Q3 report 2022 PR Newswire STOCKHOLM, Nov. 9, 2022 STOCKHOLM , Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022. "The successful directed share issue in July and the approval of Pepaxti ® in EU and EEA-countries in August, set the stage for a new and exciting phase for...

Oncopeptides announces the market potential for Pepaxti in Europe PR Newswire STOCKHOLM, Nov. 9, 2022 STOCKHOLM , Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential for Pepaxti ® in Europe . The potential assumes that the Company's pending type 2 variation submission to the European Medicines Agency based on...

Oncopeptides announces the market potential for Pepaxti in Europe PR Newswire STOCKHOLM, Nov. 9, 2022 STOCKHOLM , Nov. 9, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential for Pepaxti ® in Europe . The potential assumes that the Company's pending type 2 variation submission to the European Medicines Agency based on...

Number of shares and votes in Oncopeptides PR Newswire STOCKHOLM, Oct. 31, 2022 STOCKHOLM , Oct. 31, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company's issue of 3,940,607 new class C shares in accordance with the shareholder program Board SHP 2022 and the...

Number of shares and votes in Oncopeptides PR Newswire STOCKHOLM, Oct. 31, 2022 STOCKHOLM , Oct. 31, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company's issue of 3,940,607 new class C shares in accordance with the shareholder program Board SHP 2022 and the...

Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen PR Newswire STOCKHOLM, Oct. 26, 2022 STOCKHOLM , Oct. 26, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces data from the phase 3 LIGHTHOUSE study that further confirms the clinical benefit of melflufen in patients with relapsed refractory multiple myeloma (RRMM)....

Issue and re-purchase of class C shares for shareholder program and incentive program PR Newswire STOCKHOLM, Oct. 20, 2022 STOCKHOLM , Oct. 20, 2022 /PRNewswire/ -- The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) ("Oncopeptides"), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022 , to issue and immediately...

Issue and re-purchase of class C shares for shareholder program and incentive program PR Newswire STOCKHOLM, Oct. 20, 2022 STOCKHOLM , Oct. 20, 2022 /PRNewswire/ -- The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) ("Oncopeptides"), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022 , to issue and immediately...

Oncopeptides starts commercialization of Pepaxti in Europe - Germany first market PR Newswire STOCKHOLM, Oct. 3, 2022 STOCKHOLM , Oct. 3, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted the AMNOG dossier to "The Federal Joint Committee" (G-BA) in Germany . This initiates the commercial launch of Pepaxti® (melphalan...

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ) PR Newswire STOCKHOLM, Sept. 23, 2022 STOCKHOLM , Sept. 23, 2022 /PRNewswire/ -- An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022 . At the Extraordinary General Meeting, the following principal resolution was passed. It was resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to, until the next Annual General Meeting, on...